

# Ischemic And Anesthetic Preconditioning Of The Heart: An Insight Into The Concepts And Mechanisms

P Kalikiri, R Sachan Gajraj Singh Sachan

## Citation

P Kalikiri, R Sachan Gajraj Singh Sachan. *Ischemic And Anesthetic Preconditioning Of The Heart: An Insight Into The Concepts And Mechanisms*. The Internet Journal of Anesthesiology. 2003 Volume 8 Number 2.

## Abstract

Myocardial Preconditioning is the exposure of myocardial tissue to brief, repeated periods of vascular occlusion in order to render the myocardium resistant to the deleterious effects of prolonged episodes of ischemia or reperfusion. The period of pre-exposure and the number of times the tissue is exposed to ischemia and reperfusion vary, the average being 3 to 5 minutes. Ischemic preconditioning was first described more than a decade ago by Murray et al (1). They demonstrated a 75% reduction in infarct size caused by a 40 min coronary artery occlusion, when the occlusion was preceded by four episodes of 5 min ischemia and 5 min of reperfusion. This phenomenon has been described extensively not only in experimental animals but also in humans and has been responsible for an enormous amount of research over the last 15 years.

## INTRODUCTION TO MYOCARDIAL PRECONDITIONING

Myocardial Preconditioning is the exposure of myocardial tissue to brief, repeated periods of vascular occlusion in order to render the myocardium resistant to the deleterious effects of prolonged episodes of ischemia or reperfusion. The period of pre-exposure and the number of times the tissue is exposed to ischemia and reperfusion vary, the average being 3 to 5 minutes. Ischemic preconditioning was first described more than a decade ago by Murray et al (1). They demonstrated a 75% reduction in infarct size caused by a 40 min coronary artery occlusion, when the occlusion was preceded by four episodes of 5 min ischemia and 5 min of reperfusion. This phenomenon has been described extensively not only in experimental animals but also in humans and has been responsible for an enormous amount of research over the last 15 years. Ischemic preconditioning not only reduces the size of infarct but also protects the heart against post-infarction left ventricular dysfunction (2,3,4) and ventricular arrhythmias (5,6).

## MECHANISMS UNDERLYING ISCHEMIC PRECONDITIONING

Both an early and a late phase of preconditioning have been described. Ischemic preconditioning is associated with two forms of protection: a classical form or first window of protection lasting approximately 2-3 h after the preconditioning ischemia followed a day later by a second

window of protection (SWOP) lasting approximately 3 days. The mechanism of ischemic preconditioning involves both triggers and mediators and involves complex second messenger pathways that appear to involve such components as adenosine (7,8), adenosine receptors (9,10,11), nitric oxide (NO) (12,13,14), heat shock proteins (HSP) (15,16,17), the epsilon isoform of protein kinase C (PKC) (18,19,20), mitogen-activated protein kinases (MAPK) (21,22,23), the mitochondrial ATP-dependent potassium (K<sup>+</sup>(ATP)) channels (24,25,26), as well as others, including a paradoxical protective role of oxygen free radicals (27,28).

It is believed that ischemia induced release of endogenous agents such as adenosine and nitric oxide (NO), activation of adenosine receptors, protein kinase C (PKC), mitogen-activated protein kinases (MAPK) and opening of ATP-sensitive mitochondrial potassium (K<sup>+</sup>(ATP)) channels are the potential mechanisms of this preconditioning phenomenon.

An increase in the release of endogenous agents such as nitric oxide (NO) and adenosine may be responsible for both windows of protection, probably via different mechanisms. Nitric oxide acts as a trigger in the first window of protection via activation of a constitutive Nitric Oxide Synthase (NOS) isoform and cGMP pathway (29). Nitric oxide is also involved in the second window of protection (SWOP), however, via a different mechanism, through the activation of a protein kinase C (PKC), which in turn

activates ATP sensitive potassium (K<sup>+</sup>(ATP)) channels (29,30,31). In the second window of protection (SWOP), the origin of nitric oxide is attributed to the activity of an endothelial Nitric Oxide Synthase (eNOS) (13,14). Adenosine-induced preconditioning involves p38 MAP kinase, and mitochondrial K<sup>+</sup>(ATP) channels (7,32). Recently, it has been suggested that the K<sup>+</sup> (ATP) channels involved in the protection are mitochondrial rather than sarcolemmal (24,26).

Reactive Oxygen Species (ROS) can trigger preconditioning by causing activation of the mitochondrial K<sup>+</sup>(ATP) channel, which then induces generation of ROS and NO, which are essential for preconditioning protection (31). Activated PKC, by phosphorylation, stabilizes the open state of the mitochondrial K<sup>+</sup>(ATP) channel, which is believed to be the main end-effector in ischemic preconditioning. The opening of K<sup>+</sup>(ATP) channels ultimately confers cytoprotection by decreasing cytosolic and mitochondrial Ca (2<sup>+</sup>) overload (50,51). The stress inducible HSP70.1 and 70.3 mediate second window of protection (SWOP) (15,16), but the exact signaling pathway of this response is still under investigation.

## ANESTHETICS AND MYOCARDIAL PRECONDITIONING

Perioperative ischemia is common in patients at risk of or with known coronary artery disease undergoing noncardiac or cardiac surgery. The resultant ischemic injury that occurs during surgery can result in a significant morbidity and mortality. Some of the consequences of ischemic injury that occurs during surgery include a delay in extubation and hospital discharge, impaired quality of life after surgery, and a disproportionate consumption of health resources. The goal of anesthesiologists is to prevent this poor perioperative morbidity and mortality, which has led to a significant research in the field of anesthetic preconditioning. Experimental as well as clinical studies have shown that in addition to brief ischemia and pharmacological agents, volatile anesthetics used perioperatively also precondition the myocardium (33). Halothane (34,35), Desflurane (35), Isoflurane (34,35,36,37,38,39), and sevoflurane (35,40) have been extensively studied and these studies reveal promising results with potential clinical implications.

## MECHANISMS UNDERLYING ANESTHETIC PRECONDITIONING

Anesthetic preconditioning and ischemic preconditioning have many fundamental steps in common, including formation of nitric oxide, protein kinase C (PKC), free

radicals, activation of adenosine receptors and ATP-sensitive potassium (K<sup>+</sup>(ATP)) channels. It is believed that many anesthetics and a significant number of perioperatively administered drugs ultimately affect the activity of cardiac sarcolemmal and mitochondrial K<sup>+</sup>(ATP) channels, which are the end-effectors of cardiac preconditioning. Volatile anesthetics reduce the ischemia induced cell damage, infarct development and infarct size by causing activation of the sarcolemmal and mitochondrial K<sup>+</sup>(ATP) channels (39,41,42,43,44), by stimulation of adenosine receptors (45) and subsequent activation of protein kinase C (PKC) (46,47) and by increased formation of nitric oxide (48) and free oxygen radicals (47,49). Activated PKC then amplifies the preconditioning stimulus and by phosphorylation, stabilizes the open state of the mitochondrial K<sup>+</sup>(ATP) channel (which is believed to be the main end-effector in anesthetic preconditioning) and the sarcolemmal K<sup>+</sup>(ATP) channel. The opening of K<sup>+</sup>(ATP) channels ultimately confers cytoprotection by decreasing cytosolic and mitochondrial Ca (2<sup>+</sup>) overload (50,51).

## CORRESPONDENCE TO

Pramood C Kalikiri, M.D., PH.D. 3801 W. Napoleon Ave, Apt # B-106, Metairie, La-70122. Home Phone No: 504-909-2081. E-Mail: PKALIK@LSUHSC.EDU

## References

1. Murray CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. *Circulation* 1986; 74: 1124-36.
2. Xi L, Hess ML, Kukreja RC. Ischemic preconditioning in isolated perfused mouse heart: reduction in infarct size without improvement of post-ischemic ventricular function. *Mol Cell Biochem*. 1998 Sep; 186(1-2): 69-77.
3. Rinaldi CA, Masani ND, Linka AZ, Hall RJ. Effect of repetitive episodes of exercise induced myocardial ischaemia on left ventricular function in patients with chronic stable angina: evidence for cumulative stunning or ischaemic preconditioning? *Heart*. 1999 Apr; 81(4): 404-11.
4. Lascano EC, Negroni JA, del Valle HF, Crottogini AJ. Left ventricular regional systolic and diastolic function in conscious sheep undergoing ischemic preconditioning. *Cardiovasc Res*. 1999 Jan; 41(1): 77-86.
5. Wu ZK, Iivainen T, Pehkonen E, Laurikka J, Tarkka MR. Arrhythmias in off-pump coronary artery bypass grafting and the antiarrhythmic effect of regional ischemic preconditioning. *J Cardiothorac Vasc Anesth*. 2003 Aug; 17(4): 459-64.
6. Wu ZK, Iivainen T, Pehkonen E, Laurikka J, Tarkka MR. Ischemic preconditioning suppresses ventricular tachyarrhythmias after myocardial revascularization. *Circulation*. 2002 Dec 10; 106(24): 3091-6.
7. Zhao TC, Hines DS, Kukreja RC. Adenosine-induced late preconditioning in mouse hearts: role of p38 MAP kinase and mitochondrial K (ATP) channels. *Am J Physiol Heart Circ Physiol*. 2001 Mar; 280(3): H1278-85.
8. Schulz R, Post H, Vahlhaus C, Heusch G. Ischemic

- preconditioning in pigs: a graded phenomenon: its relation to adenosine and bradykinin. *Circulation*. 1998 Sep 8; 98(10): 1022-9.
9. Kudo M, Wang Y, Xu M, Ayub A, Ashraf M. Adenosine A (1) receptor mediates late preconditioning via activation of PKC-delta signaling pathway. *Am J Physiol Heart Circ Physiol*. 2002 Jul; 283(1): H296-301.
10. Tissier R, Souktani R, Bruneval P, Giudicelli JF, Berdeaux A, Ghaleh B. Adenosine A (1)-receptor induced late preconditioning and myocardial infarction: reperfusion duration is critical. *Am J Physiol Heart Circ Physiol*. 2002 Jul; 283(1): H38-43.
11. Schaefer S, Correa SD, Valente RJ, Laslett LJ. Blockade of adenosine receptors with aminophylline limits ischemic preconditioning in human beings. *Am Heart J*. 2001 Sep; 142(3): E4.
12. Novalija E, Hogg N, Kevin LG, Camara AK, Stowe DF. Ischemic preconditioning: triggering role of nitric oxide-derived oxidants in isolated hearts. *J Cardiovasc Pharmacol*. 2003 Nov; 42(5): 593-600.
13. Laude K, Favre J, Thuillez C, Richard V. NO produced by endothelial NO synthase is a mediator of delayed preconditioning-induced endothelial protection. *Am J Physiol Heart Circ Physiol*. 2003 Jun; 284(6): H2053-60.
14. Bell RM, Yellon DM. The contribution of endothelial nitric oxide synthase to early ischaemic preconditioning: the lowering of the preconditioning threshold. An investigation in eNOS knockout mice. *Cardiovasc Res*. 2001 Nov; 52(2): 274-80.
15. Hampton CR, Shimamoto A, Rothnie CL, Griscavage-Ennis J, Chong A, Dix DJ, Verrier ED, Pohlman TH. HSP70.1 and -70.3 are required for late-phase protection induced by ischemic preconditioning of mouse hearts. *Am J Physiol Heart Circ Physiol*. 2003 Aug; 285(2): H866-74.
16. Zhou JJ, Pei JM, Wang GY, Wu S, Wang WP, Cho CH, Wong TM. Inducible HSP70 mediates delayed cardioprotection via U-50488H pretreatment in rat ventricular myocytes. *Am J Physiol Heart Circ Physiol*. 2001 Jul; 281(1): H40-7.
17. Nayeem MA, Hess ML, Qian YZ, Loesser KE, Kukreja RC. Delayed preconditioning of cultured adult rat cardiac myocytes: role of 70- and 90-kDa heat stress proteins. *Am J Physiol*. 1997 Aug; 273(2 Pt 2): H861-8.
18. Zhang J, Ping P, Vondrisk TM, Tang XL, Wang GW, Cardwell EM, Bolli R. Cardioprotection involves activation of NF-kappa B via PKC-dependent tyrosine and serine phosphorylation of I kappa B-alpha. *Am J Physiol Heart Circ Physiol*. 2003 Oct; 285(4): H1753-8.
19. Saurin AT, Pennington DJ, Raat NJ, Latchman DS, Owen MJ, Marber MS. Targeted disruption of the protein kinase C epsilon gene abolishes the infarct size reduction that follows ischaemic preconditioning of isolated buffer-perfused mouse hearts. *Cardiovasc Res*. 2002 Aug 15; 55(3): 672-80.
20. Wolfrum S, Schneider K, Heidbreder M, Nienstedt J, Dominiak P, Dendorfer A. Remote preconditioning protects the heart by activating myocardial PKC epsilon- isoform. *Cardiovasc Res*. 2002 Aug 15; 55(3): 583-9.
21. Da Silva R, Grampp T, Pasch T, Schaub MC, Zaugg M. Differential activation of mitogen-activated protein kinases in ischemic and anesthetic preconditioning. *Anesthesiology*. 2004 Jan; 100(1): 59-69.
22. Pantos C, Malliopoulou V, Paizis I, Moraitis P, Mourouzis I, Tzeis S, Karamanoli E, Cokkinos DD, Carageorgiou H, Varonos D, Cokkinos DV. Thyroid hormone and cardioprotection: study of p38 MAPK and JNKs during ischaemia and at reperfusion in isolated rat heart. *Mol Cell Biochem*. 2003 Jan; 242(1-2): 173-180.
23. Baines CP, Zhang J, Wang GW, Zheng YT, Xiu JX, Cardwell EM, Bolli R, Ping P. Mitochondrial PKCepsilon and MAPK form signaling modules in the murine heart: enhanced mitochondrial PKCepsilon-MAPK interactions and differential MAPK activation in PKCepsilon-induced cardioprotection. *Circ Res*. 2002 Mar 8; 90(4): 390-7.
24. McCully JD, Levitsky S. Mitochondrial ATP-sensitive potassium channels in surgical cardioprotection. *Arch Biochem Biophys*. 2003 Dec 15; 420(2): 237-45.
25. Schulz R, Gres P, Heusch G. Activation of ATP-dependent potassium channels is a trigger but not a mediator of ischaemic preconditioning in pigs. *Br J Pharmacol*. 2003 May; 139(1): 65-72.
26. Ohnuma Y, Miura T, Miki T, Tanno M, Kuno A, Tsuchida A, Shimamoto K. Opening of mitochondrial K(ATP) channel occurs downstream of PKC-epsilon activation in the mechanism of preconditioning. *Am J Physiol Heart Circ Physiol*. 2002 Jul; 283(1): H440-7.
27. Skyschally A, Schulz R, Gres P, Korth HG, Heusch G. Attenuation of ischemic preconditioning in pigs by scavenging of free oxyradicals with ascorbic acid. *Am J Physiol Heart Circ Physiol*. 2003 Feb; 284(2): H698-703.
28. Das DK, Maulik N, Sato M, Ray PS. Reactive oxygen species function as second messenger during ischemic preconditioning of heart. *Mol Cell Biochem*. 1999 Jun; 196(1-2): 59-67.
29. Rakhit RD, Edwards RJ, Mockridge JW, Baydoun AR, Wyatt AW, Mann GE, Marber MS. Nitric oxide-induced cardioprotection in cultured rat ventricular myocytes. *Am J Physiol Heart Circ Physiol*. 2000 Apr; 278(4): H1211-7.
30. Uchiyama Y, Otani H, Okada T, Uchiyama T, Ninomiya H, Kido M, Imamura H, Nakao S, Shingu K. Integrated pharmacological preconditioning in combination with adenosine, a mitochondrial KATP channel opener and a nitric oxide donor. *J Thorac CardioVasc Surg*. 2003 Jul; 126(1): 148-59.
31. Lebuffe G, Schumacker PT, Shao ZH, Anderson T, Iwase H, Vanden Hoek TL. ROS and NO trigger early preconditioning: relationship to mitochondrial KATP channel. *Am J Physiol Heart Circ Physiol*. 2003 Jan; 284(1): H299-308.
32. Peart J, Headrick JP. Adenosine-mediated early preconditioning in mouse: protective signaling and concentration dependent effects. *Cardiovasc Res*. 2003 Jun 1; 58(3): 589- 601.
33. Cope DK, Impastato WK, Cohen MV, Downey JM: Volatile anesthetics protect the ischemic rabbit myocardium from infarction. *Anesthesiology* 1997; 86:699-709.
34. Warltier DC, al-Wathiqui MH, Kampine JP, Schmeling WT: Recovery of contractile function of stunned myocardium in chronically instrumented dogs is enhanced by halothane or isoflurane. *Anesthesiology* 1988; 69:552-65.
35. Piriou V, Chiari P, Lhuillier F, Bastien O, Loufoua J, Raïsky O, David JS, Ovize M, Lehot JJ. Pharmacological preconditioning: comparison of desflurane, sevoflurane, isoflurane and halothane in rabbit myocardium. *Br J Anaesth*. 2002 Sep; 89(3): 486-91.
36. Davis RF, Sidi A: Effect of isoflurane on the extent of myocardial and on systemic hemodynamics, regional myocardial blood flow, and regional myocardial metabolism in dogs after coronary artery occlusion. *Anesth Analg* 1989; 69:575-86.
37. Tanaka K, Weihrauch D, Ludwig LM, Kersten JR, Pagel PS, Warltier DC. Mitochondrial adenosine triphosphate-regulated potassium channel opening acts as a trigger for isoflurane-induced preconditioning by generating reactive oxygen species. *Anesthesiology*. 2003 Apr; 98(4): 935-43.
38. Belhomme D, Peynet J, Louzy M, Launay JM, Kitakaze

- M, Menasche P. Evidence for preconditioning by isoflurane in coronary artery bypass graft surgery. *Circulation*. 1999 Nov 9; 100(19 Suppl):II340-4.
39. Fujimoto K, Bosnjak ZJ, Kwok WM. Isoflurane-induced facilitation of the cardiac sarcolemmal K(ATP) channel. *Anesthesiology*. 2002 Jul; 97(1): 57-65.
40. Yvon A, Hanouz JL, Haelewyn B, Terrien X, Massetti M, Babatasi G, Khayat A, Ducouret P, Bricard H, Gerard JL. Mechanisms of sevoflurane-induced myocardial preconditioning in isolated human right atria in vitro. *Anesthesiology*. 2003 Jul; 99(1): 27-33.
41. Larach DR, Schuler HG: Potassium channel blockade and halothane vasodilation in conducting and resistance coronary arteries. *J Pharmacol Exp Ther* 1993; 267:72-81.
42. Cason BA, Shubayev I, Hickey RF: Blockade of adenosine triphosphate-sensitive potassium channels eliminates isoflurane-induced coronary artery vasodilation. *Anesthesiology* 1994; 81:1245-55.
43. Kersten JR, Schmeling TJ, Hettrick DA, Pagel PS, Gross GJ, Warltier DC: Mechanism of myocardial protection by isoflurane: Role of adenosine triphosphate- regulated potassium (K sub ATP) channels. *Anesthesiology* 1996; 85:794-807.
44. Zaugg M, Lucchinetti E, Spahn DR, Pasch T, Schaub MC. Volatile anesthetics mimic cardiac preconditioning by priming the activation of mitochondrial K(ATP) channels via multiple signaling pathways. *Anesthesiology*. 2002 Jul; 97(1): 4-14.
45. Kersten JR, Orth KG, Pagel PS, Mei DA, Gross GJ, Warltier DC: Role of adenosine in isoflurane-induced cardioprotection. *Anesthesiology* 1997; 86:1128-39.
46. Uecker M, Da Silva R, Grampp T, Pasch T, Schaub MC, Zaugg M. Translocation of protein kinase C isoforms to subcellular targets in ischemic and anesthetic preconditioning. *Anesthesiology*. 2003 Jul; 99(1): 138-47.
47. Novalija E, Kevin LG, Camara AK, Bosnjak ZJ, Kampine JP, Stowe DF. Reactive oxygen species precede the epsilon isoform of protein kinase C in the anesthetic preconditioning signaling cascade. *Anesthesiology*. 2003 Aug; 99(2): 421-8.
48. Novalija E, Fujita S, Kampine JP, Stowe DF. Sevoflurane mimics ischemic preconditioning effects on coronary flow and nitric oxide release in isolated hearts. *Anesthesiology*. 1999 Sep; 91(3): 701-12.
49. Novalija E, Varadarajan SG, Camara AK, An J, Chen Q, Riess ML, Hogg N, Stowe DF. Anesthetic preconditioning: triggering role of reactive oxygen and nitrogen species in isolated hearts. *Am J Physiol Heart Circ Physiol*. 2002 Jul; 283(1): H44-52.
50. An J, Varadarajan SG, Novalija E, Stowe DF. Ischemic and anesthetic preconditioning reduces cytosolic [Ca<sup>2+</sup>] and improves Ca (2+) responses in intact hearts. *Am J Physiol Heart Circ Physiol*. 2001 Oct; 281(4): H1508-23.
51. Riess ML, Camara AK, Novalija E, Chen Q, Rhodes SS, Stowe DF. Anesthetic preconditioning attenuates mitochondrial Ca<sup>2+</sup> overload during ischemia in Guinea pig intact hearts: reversal by 5-hydroxydecanoic acid. *Anesth Analg*. 2002 Dec; 95(6): 1540- 6.

**Author Information**

**Pramood C. Kalikiri, M.D., PH.D.**

Dept of Physiology, Louisiana State University Medical Center

**Reena Sachan Gajraj Singh Sachan, M.D.**

Madras Medical College